Skip to content

Percutaneous Electrical Nerve Stimulation and Exercise for Shoulder Pain

Effects of Percutaneous Electrical Nerve Stimulation and Exercise for Patients With Subacromial Pain Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06158568
Enrollment
59
Registered
2023-12-06
Start date
2023-12-01
Completion date
2024-04-27
Last updated
2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder Pain

Keywords

Neuromodulation, Percutaneous Nerve Stimulation, Exercise

Brief summary

Based on the available literature, application of percutaneous electrical nerve stimulation interventions targeting peripheral nerves (also called percutaneous neuromodulation) has shown positive effects for improving pain-related and functional outcomes in musculoskeletal chronic pain. Studies investigating the use of this intervention for the shoulder are lacking.

Detailed description

Based on the available literature, application of percutaneous electrical nerve stimulation interventions targeting peripheral nerves (also called percutaneous neuromodulation) has shown positive effects for improving pain-related and functional outcomes in musculoskeletal chronic pain. Studies investigating the use of this intervention for the shoulder are lacking.

Interventions

Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves

Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves

OTHERExercise

Application of three weeks of progressive exercises targeting the shoulder musculature

Sponsors

César Fernández-de-las-Peñas
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Unilateral non-traumatic shoulder pain (positive painful arc during shoulder abduction and a positive Hawkins test on clinical examination) * Shoulder pain from at least 3 months * Shoulder pain of more than 3/10 points on a NPRS

Exclusion criteria

* Bilateral shoulder symptoms * Younger than 18 or older than 65 years * History of shoulder traumatisms, fractures or dislocation * Diagnosis of cervical radiculopathy or myelopathy * Previous interventions with steroid injections in the shoulder area * Comorbid medical conditions, e.g., fibromyalgia syndrome * Previous history of shoulder or neck surgery * Any type of intervention for the neck-shoulder area during the previous year * Fear to needles

Design outcomes

Primary

MeasureTime frameDescription
Changes in disability between baseline and follow-up periodsBaseline, one week after the last intervention and 1 and 3 months after the interventionThe Disabilities of the Arm, Shoulder and Hand (DASH) will be used to determine the disability induced by shoulder pain

Secondary

MeasureTime frameDescription
Changes in shoulder pain between baseline and follow-up periodsBaseline, one week after the last intervention and 1 and 3 months after the interventionA 10-point Numerical Pain Rating Scale (NPRS; 0: no pain, 10: maximum pain) will be used to assess the patients' mean level of shoulder pain experienced in the preceding week in the shoulder area.
Changes in sleep quality between baseline and follow-up periodsBaseline, one week after the last intervention and 1 and 3 months after the interventionThe Pittsburgh Sleep Quality Index (PSQI) will be used to evaluate the quality of sleep
Changes in anxiety/depressive symptoms between baseline and follow-up periodsBaseline, one week after the last intervention and 1 and 3 months after the interventionThe Hospital Anxiety and Depression Scale (HADS, A: Anxiety; D: Depression) will be used to evaluate the presence of anxiety/depressive symptoms

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026